The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ...
Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.
Investigational vidofludimus calcium missed its primary target in an exploratory phase II study of progressive multiple sclerosis (MS) but showed promising disability-related trends, data from the ...
Two complementary predictors (DAAE-M and ELIE) estimate individualized 5-year progression risk using routine clinical data, ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...
Hosted on MSN
Multidisciplinary study finds estrogen could aid in therapies for progressive multiple sclerosis
About 100,000 of the estimated million people in the United States with multiple sclerosis (MS) have a progressive form of the disease, with symptoms that worsen continuously or after periods of ...
Multiple sclerosis (MS) is an inflammatory condition that damages the myelin of the central nervous system, leading to neurologic impairment and possibly severe disability. MS is characterized by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results